Weiss Ratings Reiterates "Buy (B+)" Rating for Encompass Health (NYSE:EHC)

Key Points

• Weiss Ratings has reiterated its "Buy (B+)" rating for Encompass Health (NYSE:EHC), highlighting the strong support among multiple analysts for the stock.
• Encompass Health recently received price target increases from analysts, with Bank of America raising their target from $145.00 to $160.00.
• The company's stock has a current market capitalization of $12.71 billion and is showing a positive average rating alongside an average price target of approximately $139.86.

Encompass Health (NYSE:EHC - Get Free Report)'s stock had its "buy (b+)" rating reiterated by equities research analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.

A number of other equities analysts also recently commented on EHC. KeyCorp raised their price objective on Encompass Health from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. UBS Group raised their price objective on Encompass Health from $140.00 to $150.00 and gave the stock a "buy" rating in a report on Thursday, October 2nd. Bank of America raised their target price on Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday, September 10th. Zacks Research upgraded Encompass Health from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Finally, Truist Financial raised their price objective on Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat, Encompass Health currently has an average rating of "Buy" and an average price target of $139.86.

Encompass Health Stock Down 0.2%

Encompass Health stock opened at $126.23 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The firm has a market capitalization of $12.71 billion, a price-to-earnings ratio of 24.70, a price-to-earnings-growth ratio of 2.21 and a beta of 0.93. Encompass Health has a fifty-two week low of $87.85 and a fifty-two week high of $127.99. The stock's fifty day moving average is $124.23 and its two-hundred day moving average is $118.06.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Wednesday, March 16th. The company reported $0.93 earnings per share (EPS) for the quarter. The business had revenue of $136.30 million for the quarter. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%. Encompass Health has set its FY22 guidance at $3.83-$4.19 EPS. Analysts predict that Encompass Health will post 4.8 EPS for the current fiscal year.

Insider Transactions at Encompass Health

In related news, EVP Patrick William Tuer sold 1,020 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the transaction, the executive vice president owned 18,846 shares in the company, valued at $2,329,177.14. The trade was a 5.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Encompass Health

Several institutional investors have recently bought and sold shares of EHC. Norges Bank acquired a new stake in Encompass Health in the second quarter worth about $139,536,000. Congress Asset Management Co. acquired a new stake in shares of Encompass Health during the second quarter worth $92,691,000. 8 Knots Management LLC acquired a new stake in shares of Encompass Health during the second quarter worth $78,644,000. Nuveen LLC acquired a new position in Encompass Health during the first quarter valued at $50,665,000. Finally, T. Rowe Price Investment Management Inc. raised its position in Encompass Health by 25.6% during the first quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company's stock valued at $210,756,000 after buying an additional 424,691 shares during the period. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.